Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pre-surgical Denosumab in Operable Invasive Breast Cancer
NCT02900469Phase 1Completed
- Sponsor
- NYU Langone Health
- Start
- Oct 2016
- Primary completion
- Dec 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of denosumab in breast cancer, sponsored by NYU Langone Health. Primary endpoint: Pharmacodynamic markers of RANKL inhibition determination at 1 month. Started Oct 2016; status: completed.
02
Drugs
denosumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02900469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02900469.